iTeos Therapeutics has announced it will wind down operations and cease clinical work after its TIGIT-targeting cancer therapy (belrestotug), developed with partner GSK, failed to show efficacy in lung cancer trials and GSK ended their collaboration.12
The company's board conducted a review of its pipeline, finances, and prospects before deciding to halt all clinical and operational activities.23
iTeos will seek to maximize shareholder value by selling its assets, including the experimental drugs EOS-984, EOS-215, and a preclinical obesity program targeting ENT1.345
The company’s share price rose sharply in premarket trading following the announcement, as investors anticipated returns from asset sales.2
While the wind-down has been announced, no specific timeline or details on potential buyers for the company's assets have been disclosed.23
Sources:
1. https://www.thepharmaletter.com/biotechnology/iteos-shuts-down-tigit-gsk
2. https://wkzo.com/2025/05/28/drug-developer-iteos-to-shut-down-operations-after-cancer-therapy-setback/
3. https://www.globenewswire.com/news-release/2025/05/28/3089457/0/en/iTeos-Therapeutics-Announces-Its-Intention-to-Wind-Down-Operations.html
4. https://investors.iteostherapeutics.com/news-releases/news-release-details/iteos-therapeutics-announces-its-intention-wind-down-operations
5. https://www.stocktitan.net/news/ITOS/i-teos-therapeutics-announces-its-intention-to-wind-down-iuln75u9zvss.html